{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:07:22Z","timestamp":1790759242448,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"18","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 NS111990"],"award-info":[{"award-number":["R01 NS111990"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R35 GM131839"],"award-info":[{"award-number":["R35 GM131839"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["S10 OD020012"],"award-info":[{"award-number":["S10 OD020012"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["S10 OD036329"],"award-info":[{"award-number":["S10 OD036329"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Improving siRNA delivery to the central nervous system (CNS) is a major focus for treating the numerous debilitating neurological conditions that have a genetic basis. Here, we present an albumin-binding siRNA based on an amphiphilic dendrimer conjugate (D-siRNA). We demonstrate that D-siRNA achieves effective and homogeneous delivery throughout the CNS following administration into the cerebrospinal fluid (CSF). In mice, a single CSF administration of D-siRNA resulted in potent and durable gene silencing across various brain regions, with effects lasting 6 months without detectable toxicity. We validate its utility in larger rodents (rats) using intrathecal administration\u2014a clinically relevant route\u2014showing effective and broad delivery and robust silencing. Benchmarking against other clinically relevant siRNA delivery scaffolds revealed that D-siRNA provides comparable delivery and efficacy, with more efficient conversion of gross uptake to functional uptake. These findings support the use of albumin-binding conjugates for brain delivery, and position D-siRNA as a safe, effective, and durable platform for gene silencing in the CNS.<\/jats:p>","DOI":"10.1093\/nar\/gkag926","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:01:02Z","timestamp":1789473662000},"source":"Crossref","is-referenced-by-count":0,"title":["Albumin-binding dendrimer-conjugated siRNA enables safe and effective gene silencing throughout the central nervous system"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7598-0993","authenticated-orcid":false,"given":"Hassan H","family":"Fakih","sequence":"first","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohara","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Summers","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L","family":"Sarli","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kelly","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Gagnon","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruktawit","family":"Maru","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Bramato","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-8071","authenticated-orcid":false,"given":"Anastasia","family":"Khvorova","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-1734","authenticated-orcid":false,"given":"Jonathan\u00a0K","family":"Watts","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Chan Medical School , Worcester, MA 01605 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"2026093004404894000_B1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1089\/nat.2023.0068","article-title":"Nucleic acid therapeutics: successes, milestones, and upcoming innovation","volume":"34","author":"Belgrad","year":"2024","journal-title":"Nucleic Acid Ther"},{"key":"2026093004404894000_B2","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2026093004404894000_B3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1039\/9781837671328","article-title":"Nucleic Acid Therapeutics","volume-title":"Nucleic Acids in Chemistry and Biology","author":"Watts","year":"2022"},{"key":"2026093004404894000_B4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026093004404894000_B5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2026093004404894000_B6","doi-asserted-by":"publisher","first-page":"177529","DOI":"10.1016\/j.ejphar.2025.177529","article-title":"Oligonucleotide-based therapeutics for neurodegenerative disorders: focus on antisense oligonucleotides","volume":"998","author":"Mansour","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"2026093004404894000_B7","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2026093004404894000_B8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026093004404894000_B9","doi-asserted-by":"publisher","first-page":"102742","DOI":"10.1016\/j.omtn.2025.102742","article-title":"Comparison of MALAT1 antisense oligonucleotide distribution following intracerebroventricular and lumbar intrathecal routes of administration","volume":"36","author":"Boyd","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026093004404894000_B10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2967\/jnumed.125.270731","article-title":"Central nervous system biodistribution and pharmacokinetics of radiolabeled tofersen in rodents, nonhuman primates, and humans","volume":"67","author":"Cook","year":"2026","journal-title":"J Nucleic Med"},{"key":"2026093004404894000_B11","doi-asserted-by":"publisher","first-page":"e129240","DOI":"10.1172\/jci.insight.129240","article-title":"Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging","volume":"4","author":"Mazur","year":"2019","journal-title":"JCI Insight"},{"key":"2026093004404894000_B12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","article-title":"The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration","volume":"49","author":"Jafar-nejad","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026093004404894000_B13","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/nbt1339","article-title":"Mechanisms and optimization of in vivo delivery of lipophilic siRNAs","volume":"25","author":"Wolfrum","year":"2007","journal-title":"Nat Biotechnol"},{"key":"2026093004404894000_B14","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/nar\/gky1232","article-title":"Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways","volume":"47","author":"Osborn","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026093004404894000_B15","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1093\/nar\/gkae260","article-title":"Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo","volume":"52","author":"Sarli","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2026093004404894000_B16","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1038\/mtna.2015.38","article-title":"Hydrophobically modified siRNAs silence Huntingtin mRNA in primary neurons and mouse brain","volume":"4","author":"Alterman","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026093004404894000_B17","doi-asserted-by":"publisher","first-page":"7355","DOI":"10.1021\/jacs.7b02917","article-title":"Development of DNA nanostructures for high-affinity binding to human serum albumin","volume":"139","author":"Lacroix","year":"2017","journal-title":"J Am Chem Soc"},{"key":"2026093004404894000_B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2020.04.020","article-title":"Detailed cellular assessment of albumin-bound oligonucleotides: increased stability and lower non-specific cell uptake","volume":"324","author":"Lacroix","year":"2020","journal-title":"J Control Release"},{"key":"2026093004404894000_B19","doi-asserted-by":"publisher","first-page":"102080","DOI":"10.1016\/j.omtn.2023.102080","article-title":"Dendritic amphiphilic siRNA: selective albumin binding, in vivo efficacy, and low toxicity","volume":"34","author":"Fakih","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026093004404894000_B20","doi-asserted-by":"publisher","first-page":"102579","DOI":"10.1016\/j.omtn.2025.102579","article-title":"Albumin-binding dendritic siRNA improves delivery and efficacy to solid tumors in a melanoma model","volume":"36","author":"Fakih","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026093004404894000_B21","doi-asserted-by":"publisher","first-page":"e40070","DOI":"10.7554\/eLife.40070","article-title":"Aquaporin-4-dependent glymphatic solute transport in the rodent brain","volume-title":"eLife","author":"Mestre","year":"2018"},{"key":"2026093004404894000_B22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jneumeth.2018.09.031","article-title":"Quantitative and qualitative assessment of glymphatic flux using Evans blue albumin","volume":"311","author":"Wolf","year":"2019","journal-title":"J Neurosci Methods"},{"key":"2026093004404894000_B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000546286","article-title":"The glymphatic system in cerebrospinal fluid dynamics: clinical implications, its evaluation, and application to therapeutics","volume":"25","author":"Ohara","year":"2025","journal-title":"Neurodegener Dis"},{"key":"2026093004404894000_B24","doi-asserted-by":"publisher","first-page":"gkaf600","DOI":"10.1093\/nar\/gkaf600","article-title":"Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid\u2013siRNA conjugate administered into cerebrospinal fluid","volume":"53","author":"Sorets","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"2026093004404894000_B25","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1111\/epi.18278","article-title":"Durable suppression of seizures in a preclinical model of KCNT1 genetic epilepsy with divalent small interfering RNA","volume":"66","author":"Andreone","year":"2025","journal-title":"Epilepsia"},{"key":"2026093004404894000_B26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkag287","article-title":"Divalent siRNA for prion disease","volume":"54","author":"Gentile","year":"2026","journal-title":"Nucleic Acids Res"},{"key":"2026093004404894000_B27","doi-asserted-by":"publisher","first-page":"102117","DOI":"10.1016\/j.omtn.2024.102117","article-title":"Multispecies-targeting siRNAs for the modulation of JAK1 in the skin","volume":"35","author":"Tang","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026093004404894000_B28","doi-asserted-by":"publisher","first-page":"8877","DOI":"10.1038\/s41467-026-75611-7","article-title":"Single-dose administration of therapeutic divalent siRNA targeting MECP2 prevents lethality in an MECP2 duplication mouse model","volume":"17","author":"Hariharan","year":"2026","journal-title":"Nat Commun"},{"key":"2026093004404894000_B29","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.omtn.2024.102359","article-title":"Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation","volume":"35","author":"Miller","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026093004404894000_B30","first-page":"129","article-title":"Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age","volume":"33","author":"Blennow","year":"1993","journal-title":"Eur Neurol"},{"key":"2026093004404894000_B31","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1093\/nar\/gkae368","article-title":"A programmable dual-targeting siRNA scaffold supports potent two-gene modulation in the central nervous system","volume":"52","author":"Belgrad","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2026093004404894000_B32","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1016\/j.ymthe.2024.10.024","article-title":"Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system","volume":"32","author":"Moazami","year":"2024","journal-title":"Mol Ther"},{"key":"2026093004404894000_B33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/01926233231218953","article-title":"Toxicologic pathology forum: opinion on interpretive challenges for procedure-related effects associated with direct central nervous system delivery of oligonucleotides to rodents, dogs, and nonhuman primates","volume":"51","author":"Berman-Booty","year":"2023","journal-title":"Toxicol Pathol"},{"key":"2026093004404894000_B34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-7-8","article-title":"Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis","volume":"7","author":"Graber","year":"2010","journal-title":"J Neuroinflam"},{"key":"2026093004404894000_B35","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Tang","year":"2023","journal-title":"Nat Commun"},{"key":"2026093004404894000_B36","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.ymthe.2020.12.023","article-title":"Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles","volume":"29","author":"Biscans","year":"2021","journal-title":"Mol Ther"},{"key":"2026093004404894000_B37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1089\/nat.2017.0690","article-title":"Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to peptide nucleic acid hybridization assay","volume":"27","author":"Godinho","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"2026093004404894000_B38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40478-021-01220-8","article-title":"Mouse closed head traumatic brain injury replicates the histological tau pathology pattern of human disease: characterization of a novel model and systematic review of the literature","volume":"9","author":"Kahriman","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"2026093004404894000_B39","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/nar\/gky1260","article-title":"Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay","volume":"47","author":"Gaus","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026093004404894000_B40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/bdd.2338","article-title":"Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: advances, challenges, and future perspectives","volume":"44","author":"Goto","year":"2023","journal-title":"Biopharm Drug Dispos"},{"key":"2026093004404894000_B41","article-title":"Alnylam reports additional positive interim phase 1 results for ALN-APP","volume-title":"Development for Alzheimer\u2019s Disease and Cerebral Amyloid Angiopathy","author":"Regan\u00a0Lindenboom\u00a0C,\u00a0Brodsky","year":"2023"},{"key":"2026093004404894000_B42","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/21593337251371594","article-title":"Cell type distribution of intrathecal antisense oligonucleotide activity in deep brain regions of non-human primates","volume":"35","author":"Frei","year":"2025","journal-title":"Nucleic Acid Ther"},{"key":"2026093004404894000_B43","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.1093\/nar\/gkad371","article-title":"A single-cell map of antisense oligonucleotide activity in the brain","volume":"51","author":"Mortberg","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2026093004404894000_B44","doi-asserted-by":"publisher","first-page":"102692","DOI":"10.1016\/j.omtn.2025.102692","article-title":"Unraveling and controlling late-onset neurotoxicity of antisense oligonucleotides through strategic chemical modifications","volume":"36","author":"Kuroda","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026093004404894000_B45","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/nar\/gky1239","article-title":"Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo","volume":"47","author":"Biscans","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026093004404894000_B46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"2026093004404894000_B47","doi-asserted-by":"publisher","first-page":"e154142","DOI":"10.1172\/jci.insight.154142","article-title":"Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy","volume":"7","author":"Hammond","year":"2022","journal-title":"JCI Insight"},{"key":"2026093004404894000_B48","doi-asserted-by":"publisher","first-page":"eadi2245","DOI":"10.1126\/scitranslmed.adi2245","article-title":"Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier","volume":"16","author":"Barker","year":"2024","journal-title":"Sci Transl Med"}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/54\/18\/gkag926\/71502506\/gkag926.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/54\/18\/gkag926\/71502506\/gkag926.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:41:00Z","timestamp":1790757660000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/doi\/10.1093\/nar\/gkag926\/8852168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":48,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkag926","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,14]]},"published":{"date-parts":[[2026,9,22]]},"article-number":"gkag926"}}